To investigate the safety and efficacy of tamsulosin combined with mirabelone in the treatment of benign prostatic hyperplasia (BPH) with overactive bladder (OAB).

From September 2019 to December 2020, 70 patients diagnosed with BPH combined with OAB in the Urology Department of Wuhan University People's Hospital were selected and included in this study. The patients were divided into Group A and Group B, 35 cases in each group by random number table method in accordance with 1∶1 ratio. In group A, tamsolocine was used only (0.2 mg, once per day). In group B, tamsoroxine (0.2 mg, once per day) and mirabellon (50 mg, once per day) were administered simultaneously. At baseline and after 12 weeks symptoms improvement [international prostate symptom score (IPSS), urine storage period symptom scores (USPSS), voiding symptom scores (VSS), bladder excessive activity score (OABSS)], urine flow mechanics parameters change situation [maximum urinary flow rate (Q_max), residual urine volume (RUV)] and the incidence of drug related adverse reaction were compared between the two groups.

A total of 65 patients (92.86%) with BPH and OAB were followed up reliably, with an average age of 62 (50-80) years. At the end of treatment (12 weeks), symptom scores of each stage and Q_max of the two groups were significantly improved compared with their corresponding baseline levels, and the differences were statistically significant (P<0.05). There was no significant difference in RUV between the two groups before and after treatment (all P was >0.05). After the end of treatment, IPSS, USPSS and OABSS in group B were significantly reduced compared with group A, and the differences were statistically significant (All P<0.05). In terms of VSS, Q_max and RUV, there were no statistically significant differences between group B and group A after treatment (all P>0.05). No serious adverse reactions occurred in both groups, with 10 patients (15.38%) suffering at least one adverse event.

The combination of tamsoroxin and mirabelone in the treatment of mild and moderate obstruction symptoms of BPH combined with OAB showed significant efficacy, which was superior to that of tamsoroxine alone, and no significant increase in drug-related adverse reactions was observed.